Amgen
AMGN
#72
Rank
$180.06 B
Marketcap
$335.67
Share price
0.76%
Change (1 day)
47.33%
Change (1 year)

The biotechnology company Amgen was founded in 1980 as AMGen. With approximately 20,000 employees, Amgen is one of the world's largest biotechnology companies with annual sales of approximately $ 24 billion in 2018.

P/E ratio for Amgen (AMGN)

P/E ratio as of July 2024 (TTM): 23.7

According to Amgen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 23.7223. At the end of 2022 the company had a P/E ratio of 21.6.

P/E ratio history for Amgen from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202221.6-0.7%
202121.717.02%
202018.6-0.31%
201918.621.35%
201815.3-76.8%
201766.1366.71%
201614.2-20.05%
201517.7-24.46%
201423.538.6%
201316.99.96%
201215.4-2.67%
201115.838.85%
201011.4-8.79%
200912.5-18.26%
200815.3-7.89%
200716.6-39.3%
200627.32.56%
200526.6-22.75%
200434.5-2.88%
200335.5-167.58%
2002-52.5-198.68%
200153.2

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
16.1-31.94%๐Ÿ‡บ๐Ÿ‡ธ USA
10.9-54.18%๐Ÿ‡บ๐Ÿ‡ธ USA
11.4-52.03%๐Ÿ‡ฌ๐Ÿ‡ง UK
16.7-29.61%๐Ÿ‡บ๐Ÿ‡ธ USA
12.4-47.86%๐Ÿ‡บ๐Ÿ‡ธ USA
47.6 100.74%๐Ÿ‡บ๐Ÿ‡ธ USA
11.1-53.14%๐Ÿ‡บ๐Ÿ‡ธ USA
-4.51-118.99%๐Ÿ‡บ๐Ÿ‡ธ USA
167 603.12%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.